RU2700582C2 - Схема применения соединения fgf-18 - Google Patents

Схема применения соединения fgf-18 Download PDF

Info

Publication number
RU2700582C2
RU2700582C2 RU2016137292A RU2016137292A RU2700582C2 RU 2700582 C2 RU2700582 C2 RU 2700582C2 RU 2016137292 A RU2016137292 A RU 2016137292A RU 2016137292 A RU2016137292 A RU 2016137292A RU 2700582 C2 RU2700582 C2 RU 2700582C2
Authority
RU
Russia
Prior art keywords
cartilage
fgf
treatment
weeks
compound
Prior art date
Application number
RU2016137292A
Other languages
English (en)
Russian (ru)
Other versions
RU2016137292A3 (https=
RU2016137292A (ru
Inventor
Кристоф Х. ЛАДЕЛ
Ханс ГЮРИНГ
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU2016137292A publication Critical patent/RU2016137292A/ru
Publication of RU2016137292A3 publication Critical patent/RU2016137292A3/ru
Application granted granted Critical
Publication of RU2700582C2 publication Critical patent/RU2700582C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016137292A 2014-02-20 2015-02-20 Схема применения соединения fgf-18 RU2700582C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
EP14000600.8 2014-02-20
PCT/EP2015/053631 WO2015124731A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
RU2016137292A RU2016137292A (ru) 2018-03-21
RU2016137292A3 RU2016137292A3 (https=) 2018-09-17
RU2700582C2 true RU2700582C2 (ru) 2019-09-18

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016137292A RU2700582C2 (ru) 2014-02-20 2015-02-20 Схема применения соединения fgf-18
RU2016137289A RU2691946C2 (ru) 2014-02-20 2015-02-20 Схема применения соединения fgf-18

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016137289A RU2691946C2 (ru) 2014-02-20 2015-02-20 Схема применения соединения fgf-18

Country Status (25)

Country Link
US (2) US9724388B2 (https=)
EP (2) EP3107559B1 (https=)
JP (2) JP6431083B2 (https=)
KR (2) KR102410986B1 (https=)
CN (2) CN106232622A (https=)
AR (2) AR099558A1 (https=)
AU (2) AU2015220773B2 (https=)
BR (2) BR112016018685A2 (https=)
CA (1) CA2938791A1 (https=)
DK (2) DK3107559T3 (https=)
ES (2) ES2688551T3 (https=)
HR (2) HRP20181572T1 (https=)
HU (1) HUE040350T2 (https=)
IL (2) IL247083B (https=)
LT (2) LT3107559T (https=)
MX (2) MX2016010871A (https=)
NZ (1) NZ723148A (https=)
PL (2) PL3107559T3 (https=)
PT (2) PT3119417T (https=)
RS (2) RS57853B1 (https=)
RU (2) RU2700582C2 (https=)
SG (2) SG11201606502YA (https=)
SI (2) SI3107559T1 (https=)
WO (2) WO2015124731A1 (https=)
ZA (2) ZA201605548B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2700582C2 (ru) 2014-02-20 2019-09-18 Мерк Патент Гмбх Схема применения соединения fgf-18
NZ723177A (en) 2014-02-20 2021-12-24 Merck Patent Gmbh Implant comprising fgf-18
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
MX384205B (es) 2016-02-22 2025-03-14 Novartis Ag Metodos para usar agonistas de fxr.
EP3687558B1 (en) 2017-09-29 2022-03-16 Merck Patent GmbH Metabolic biomarkers for predicting responsiveness to fgf-18 compound
LT3688468T (lt) * 2017-09-29 2022-06-27 Merck Patent Gmbh Uždegiminiai biožymenys, skirti atsako į fgf-18 junginį numatymui
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
IL285420B1 (en) * 2019-02-08 2026-04-01 Merck Patent Gmbh Treatment for patients at risk of rapid progression of osteoarthritis
KR102920449B1 (ko) * 2023-03-29 2026-02-03 주식회사 아이프로테인테라퓨틱스 인터류킨-1 수용체 길항제 변이체 및 이의 용도
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023063A2 (en) * 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
ES2706848T3 (es) * 2004-07-06 2019-04-01 Zymogenetics Inc Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso
AU2006326870A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents
ZA200900426B (en) * 2006-08-25 2010-04-28 Ares Trading Sa Treatment of cartilage disorders with FGF-18
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
WO2012127506A1 (en) * 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
RU2700582C2 (ru) 2014-02-20 2019-09-18 Мерк Патент Гмбх Схема применения соединения fgf-18
WO2015124735A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Fgf-18 in graft transplantation and tissue engineering procedures
NZ723177A (en) 2014-02-20 2021-12-24 Merck Patent Gmbh Implant comprising fgf-18

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008023063A2 (en) * 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
EA015644B1 (ru) * 2006-08-25 2011-10-31 Арес Трейдинг С.А. Способ лечения заболеваний хряща

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOORE E. E. et al.: "Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis" //Transcripts of the annual meeting of the orthopaedic research society, XX, XX, vol. 13, 7 March 2004 (2004-03-07), pages 623-631. *
ЧИССОВ В.И. и др. Онкология. Национальное руководство//М., "ГЭОТАР-Медиа", 2008, с.124 строка 6. *
ЧИССОВ В.И. и др. Онкология. Национальное руководство//М., "ГЭОТАР-Медиа", 2008, с.124 строка 6. MOORE E. E. et al.: "Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis" //Transcripts of the annual meeting of the orthopaedic research society, XX, XX, vol. 13, 7 March 2004 (2004-03-07), pages 623-631. *

Also Published As

Publication number Publication date
HRP20181572T1 (hr) 2018-11-30
PT3119417T (pt) 2018-10-31
RU2016137289A (ru) 2018-03-21
RU2691946C2 (ru) 2019-06-19
CA2938791A1 (en) 2015-08-27
KR20160116001A (ko) 2016-10-06
LT3119417T (lt) 2018-10-25
CN106232622A (zh) 2016-12-14
AU2015220773B2 (en) 2020-10-08
RU2016137292A3 (https=) 2018-09-17
EP3107559B1 (en) 2018-07-11
US9724388B2 (en) 2017-08-08
BR112016018696A2 (pt) 2017-10-17
CA2938793A1 (en) 2015-08-27
IL247083A0 (en) 2016-09-29
ES2688551T3 (es) 2018-11-05
AU2015220773A1 (en) 2016-09-01
RU2016137289A3 (https=) 2018-10-19
KR102410988B1 (ko) 2022-06-17
IL247084A0 (en) 2016-09-29
EP3119417B1 (en) 2018-07-11
DK3107559T3 (en) 2018-10-15
HUE040350T2 (hu) 2019-03-28
SI3107559T1 (sl) 2018-11-30
IL247084B (en) 2019-09-26
SI3119417T1 (sl) 2018-11-30
MX2016010871A (es) 2016-11-17
ZA201605548B (en) 2018-12-19
HRP20181570T1 (hr) 2018-11-30
PL3107559T3 (pl) 2019-01-31
AR099510A1 (es) 2016-07-27
CN106456713A (zh) 2017-02-22
PL3119417T3 (pl) 2019-01-31
AU2015220777B2 (en) 2020-10-22
US20170056474A1 (en) 2017-03-02
AR099558A1 (es) 2016-08-03
ES2689071T3 (es) 2018-11-08
WO2015124731A1 (en) 2015-08-27
EP3119417A1 (en) 2017-01-25
US20170072017A1 (en) 2017-03-16
JP6431083B2 (ja) 2018-11-28
KR102410986B1 (ko) 2022-06-17
SG11201606502YA (en) 2016-09-29
US9889179B2 (en) 2018-02-13
PT3107559T (pt) 2018-10-31
EP3107559A1 (en) 2016-12-28
DK3119417T3 (en) 2018-10-22
RS57853B1 (sr) 2018-12-31
NZ723139A (en) 2022-12-23
NZ723148A (en) 2022-08-26
JP2017512194A (ja) 2017-05-18
WO2015124727A1 (en) 2015-08-27
BR112016018685A2 (pt) 2017-10-17
MX2016010872A (es) 2016-11-17
RS57709B1 (sr) 2018-12-31
JP2017507142A (ja) 2017-03-16
AU2015220777A1 (en) 2016-09-01
RU2016137292A (ru) 2018-03-21
SG11201606505UA (en) 2016-09-29
IL247083B (en) 2019-09-26
KR20160116000A (ko) 2016-10-06
ZA201605547B (en) 2019-09-25
LT3107559T (lt) 2018-10-25
JP6431082B2 (ja) 2018-11-28

Similar Documents

Publication Publication Date Title
RU2700582C2 (ru) Схема применения соединения fgf-18
KR101419961B1 (ko) Ｆｇｆ-18 로 연골 질환의 치료
US20240293514A1 (en) Pharmaceutical compositions comprising glp-1r agonists
EP4108252A1 (en) Pharmaceutical compositions comprising glp-1r agonists
EP2502632B1 (en) Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis
CA2938793C (en) Fgf-18 compound dosing regimen
RU2745453C2 (ru) Комбинированная композиция, содержащая соединение fgf-18
CN111212652A (zh) 骨关节炎疼痛的新疗法
HK40085325A (en) Pharmaceutical compositions comprising glp-1r agonists
HK1231895A1 (en) Fgf-18 compound dosing regimen
HK1231754A1 (zh) Fgf-18化合物给药方案
HK1129852A (en) Treatment of cartilage disorders
HK1129852B (en) Treatment of cartilage disorders